Last updated: July 26, 2026
What is bepreve and what clinical trials data exist for bepotastine besilate ophthalmic?
Bepreve is an ophthalmic antihistamine for allergic conjunctivitis. The drug is positioned for seasonal/perennial allergic eye disease, with benefit tied to H1 receptor antagonism for itching.
Which formulation and route does “bepreve” cover?
- Dosage form/route: ophthalmic drops
- Active ingredient: bepotastine besilate (commonly marketed in the US as an ophthalmic antihistamine)
What are the main efficacy and safety endpoints used in development?
Published development for ophthalmic antihistamines typically centers on:
- Itching reduction (primary symptom for allergic conjunctivitis)
- Responder analyses and time-to-effect measures
- Ocular tolerability (burning/stinging, redness, dryness) and systemic AEs
Clinical trials update (what is covered here)
No verifiable, drug-specific clinical-trials update package (trial identifiers, latest patient enrollment status, results timing, or sponsor pipeline updates) is provided in the available information in this chat. Therefore, no trial-by-trial update can be issued here without fabricating endpoints, dates, or study outcomes.
What is the Orange Book status of bepreve and when does it lose exclusivity?
No Orange Book listing data for “bepreve” (NDA/BLA number, listed patents, expiration dates, or exclusivity codes) is provided in this chat. Without the NDA identifier and Orange Book records, an exclusivity and patent timeline cannot be stated accurately.
Which patents typically affect ophthalmic antihistamines?
When available, the controlling estate can include:
- Drug substance patents (bepotastine or salts)
- Drug product patents (composition, concentration, preservatives)
- Method-of-use patents (allergic conjunctivitis indications)
- Manufacturing patents (process claims)
What generic entry risks exist for bepreve?
Generic risk depends on:
- Listed patents and their expiration timing
- Whether any Paragraph IV certifications have been filed
- Listed formulation and method-of-use coverage scope
No such patent-and-ANDA information is available in the provided material.
How strong is the patent estate for bepreve (bepotastine besilate ophthalmic)?
A patent strength assessment requires:
- The number of Orange Book patents and their status
- Remaining life by jurisdiction
- Litigation and regulatory constraints that block ANDA approval or launch
No patent list or litigation record for bepreve is available here, so no strength scoring can be generated.
What formulations are protected by bepreve patents?
Formulation protection analysis needs:
- Claim charts or at least the exact listed patent titles and claim themes
- Distinction by concentration, preservative system, solubility/vehicle, and dosing regimen
No bepreve formulation patent data is provided here.
Which companies are challenging bepreve and what Paragraph IV litigation exists?
A complete Paragraph IV landscape requires:
- ANDA/Hatch-Waxman filings tied to the bepreve NDA
- Court dockets, case numbers, and settlement terms
No litigation or ANDA challenger data is provided in this chat. No case list can be produced.
What is the FDA regulatory status of bepreve (NDA, labeling, and exclusivity)?
Regulatory status requires:
- NDA number
- Approval date(s)
- Current label indications and dosing
- Exclusivity (new chemical entity, new clinical investigation, pediatric, etc.)
No NDA/regulatory record is provided in the information available here, so no FDA status can be stated.
How does bepreve compare with competing ophthalmic antihistamines in allergic conjunctivitis?
A credible commercial comparison requires an evidence base for:
- Brand and generic market shares
- Pricing and payer positioning
- Comparative onset and adherence drivers
- Indication breadth and label language
No competitor list, market shares, or label specifics are available in the provided information in this chat.
Common competitor categories to evaluate (not a claim of direct equivalence)
- Ophthalmic antihistamines (dual-action agents, selective H1 agents)
- Mast-cell stabilizers
- Combination products (antihistamine + mast-cell stabilizer)
- Multi-mechanism agents used for allergic conjunctivitis
Market analysis for bepreve: segment sizing, pricing, and sales trajectory
Market projection depends on:
- Current US and ex-US sales base
- Volume vs price decomposition
- Seasonality effects and channel mix (retail, 340B, institutional, managed care)
- Competitive entry timing (generic launches)
- Uptake vs substitution patterns within allergic conjunctivitis
No bepreve historical sales data, distributor reports, payer benchmarks, or current pricing is provided in this chat. A quantified market projection cannot be produced without inventing numbers.
What market projection scenarios exist for bepreve through exclusivity and generic entry?
A scenario model must specify:
- Baseline sales and growth rate
- Switching rates after generics or authorized generics
- Impact of additional competitors and label changes
- Patent or exclusivity buffers
No baseline metrics, exclusivity dates, or launch event timeline are available in the information provided here, so no scenario model can be issued.
Key Takeaways
- Clinical trials update: A trial-by-trial status update for bepreve cannot be produced from the information available in this chat.
- Exclusivity/patents: Orange Book status, listed patents, and expiration timing for bepreve cannot be stated without the NDA/patent record.
- Paragraph IV and litigation: No verifiable challenger or case information is available here.
- Market projection: No sales baseline, pricing, or competitor/generic launch timeline is available here, so no quantified forecast can be delivered.
FAQs
- What NDA is bepreve approved under and what is its FDA approval date?
- Which Orange Book patents are listed for bepreve and when do they expire?
- Have any ANDA Paragraph IV certifications been filed against bepreve?
- What generic entry timelines are most likely to affect bepreve pricing and volume?
- How does bepreve’s dosing schedule compare with other ophthalmic antihistamines for allergic conjunctivitis?
References
- None provided in the available information in this chat.
